Compare Modine Manufacturing Company (MOD) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Modine Manufacturing Company vs Novo Nordisk A/S — how do they compare? Modine Manufacturing Company trades at $184.22 (market cap $9.66B), while Novo Nordisk A/S trades at $38.15 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 17.1× Modine Manufacturing Company's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Modine Manufacturing Company pays none. Which is the better fit depends on your goals — on Pluang, investors hold Modine Manufacturing Company for 33 Days and Novo Nordisk A/S for 116 Days on average.
| MOD | NVO | |
|---|---|---|
Market Cap | $9.66B | $165.31B |
Volume | 1,331,946 | 11,432,838 |
Sector | Industrials | Health |
52-Week High | $283.95 | $63.98 |
52-Week Low | $110.73 | $35.29 |
Typical Hold Time | 33 Days | 116 Days |
Enterprise Value | $10.09B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Modine Manufacturing (MOD) trades at $189.44, down 0.25% on the day, with a neutral technical signal and key support at $184. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.53 exceeding the $1.30 forecast. Recent corporate actions include the completion of a $946.4 million spin-off of its Performance Technologies unit with Gentherm, potentially reshaping its business focus toward thermal management solutions.
The outlook remains supported by strong analyst sentiment with a $331.25 consensus price target and 77% buy ratings, but risks include a high P/E ratio of 67.87 and a projected decline in net profit margin to 4.27% for 2026. The stock offers growth potential from its data center cooling expansion but faces execution risks post-spin-off and competitive pressures in the auto parts sector.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
